identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo
On reacting the 3-aminopyridazines 1a,d,e with dimethyl acetylenedicarboxylate (DMAD), the pyrimido[1,2-b]pyridazin-2-(2H)-ones 2e-g, whereas starting from 1f, the 4(4H)-ones 5a and 3b,d were prepared. In the 2(2H)-one series, the reactions of 2b with various amino compounds resulted in various types of products. The reaction of N-methylaminopyridazines 1g,h with DMAD led to the endo-N-substituted
3-氨基哒嗪1a,d,e与乙炔二甲酸二甲酯(DMAD)反应后,嘧啶并[1,2 - b ]哒嗪-2-(2 H)-ones 2e-g,而从1f开始,4(4制备了H 5 -one 5a和3b,d。在2(2 H)-one系列中,2b与各种氨基化合物的反应生成各种类型的产物。N-甲基氨基哒嗪1g,h与DMAD的反应生成了N-取代的内衍生物8a,b,而1h用乙氧基亚甲基丙二酸二乙酯(DEM)制得外-N-取代的化合物1k。化合物的组成已通过光谱和化学证据证明。
PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR
申请人:Cisen Pharmaceutical Co., Ltd.
公开号:EP3159342A1
公开(公告)日:2017-04-26
Disclosed is a pyridino[1, 2-a]pyrimidone analogue used as an mTOR/PI3K inhibitor. The present invention particularly relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
[EN] PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR<br/>[FR] ANALOGUE DE PYRIDINO [1,2-A] PYRIMIDONE UTILISÉ EN TANT QU'INHIBITEUR DE PI3K/MTOR<br/>[ZH] 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物